Compare ETJ & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETJ | EMBC |
|---|---|---|
| Founded | N/A | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 543.8M | 524.1M |
| IPO Year | 2007 | 2021 |
| Metric | ETJ | EMBC |
|---|---|---|
| Price | $8.46 | $9.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 197.9K | ★ 766.9K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | ★ 6.24% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.88 | $8.47 |
| 52 Week High | $9.12 | $15.55 |
| Indicator | ETJ | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 57.54 |
| Support Level | N/A | $8.60 |
| Resistance Level | $9.03 | $10.88 |
| Average True Range (ATR) | 0.12 | 0.35 |
| MACD | 0.07 | 0.14 |
| Stochastic Oscillator | 87.86 | 82.87 |
Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.